



● Bardoxolone Methyl n=261
○ Placebo n=297

● Bardoxolone Methyl n=260
○ Placebo n=288

● Bardoxolone Methyl n=170
○ Placebo n=183

● Bardoxolone Methyl n=264
○ Placebo n=274

Study Week

● Bardoxolone Methyl n=178
○ Placebo n=185

● Bardoxolone Methyl n=71
○ Placebo n=74

Figure S1. BEACON Patients in the Lowest Quartile of Baseline Hepatic Enzyme Values
 Mean [± SEM] ALT, AST, and GGT [U/L] through 48 weeks of treatment for patients in the lowest quartile of baseline values randomized to bardoxolone methyl or placebo. Patients in the lowest quartile had baseline serum concentrations of ALT ≤ 13.6 U/L, AST ≤ 15.8 U/L, and GGT ≤ 15.3 U/L.